Clinical Trials on 2019 nCoV, PD-1 in Belgium

Total 3 results

Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Recruiting

Respiratory Virus Hospitalization Study (FLU 003 Plus)

Influenza | Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) | Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)

United States, Australia, Spain, Denmark, Greece, Argentina, United Kingdom, Belgium, Chile, Germany, Peru, Thailand
Azienda Ospedaliera Universitaria Integrata Verona
Charite University, Berlin, Germany; Institut National de la Santé Et de la... and other collaborators

Recruiting

Follow-up of Covid-19 Long Term Sequelae

Coronavirus Infections | Covid19 | Coronavirus Disease 2019 | Corona Virus Infection | Coronavirus | SARS-CoV2 Infection | COVID-19 Pneumonia | SARS-CoV-2 Acute Respiratory Disease | SARS (Severe Acute Respiratory Syndrome) | COVID-19 Respiratory Infection | SARS (Disease) | COVID-19 Acute Respiratory Distress... and other conditions

Italy, Belgium, Congo, France, Netherlands, Spain

Clinical Trials on 2019 nCoV, PD-1 in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations